

BIBLIOGRAPHY

ADA (American Diabetes Association) Professional Practice Committee (2021) ‘9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Medical Care in Diabetes—2022*’. *Diabetes Care* 1 January 2022; 45 (Supplement_1): S125–S143. <https://doi.org/10.2337/dc22-S009>

Berumen, Jaime, et al. “Sex Differences in the Influence of Type 2 Diabetes (T2D)-Related Genes, Parental History of T2D, and Obesity on T2D Development: A Case–Control Study.” *Biology of Sex Differences*, vol. 14, no. 1, 8 June 2023, <https://doi.org/10.1186/s13293-023-00521-y>.

Brutsaert, E.F. (2023) Diabetes mellitus (DM) - hormonal and metabolic disorders, MSD Manual Consumer Version. Available at: <https://www.msdmanuals.com/en-sg/home/hormonal-and-metabolic-disorders/diabetes-mellitus-dm-and-disorders-of-blood-sugar-metabolism/diabetes-mellitus-dm>. (Accessed: 06 February 2024).

Brutsaert, E.F. (2023) Diabetes mellitus (DM), MSD Manual Professional Version. Available at: <https://www.msdmanuals.com/en-sg/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/diabetes-mellitus-dm> (Accessed: 06 February 2024).

Carney, G. *et al.* (2022) ‘Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada’, *BMJ Open Diabetes Research & Care*, 10(6). doi:10.1136/bmjdr-2022-002995.

Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S., Saboo, B., Kalra, S., & RSSDI-ESI Consensus Group (2020). ‘RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020’, *Indian Journal of Endocrinology and Metabolism*, 24(1), 1–122. https://doi.org/10.4103/ijem.IJEM_225_20

Cicek, Meryem, et al. “Characterizing Multimorbidity from Type 2 Diabetes.” *Endocrinology and Metabolism Clinics of North America*, vol. 50, no. 3, Sept. 2021, pp. 531–558, <https://doi.org/10.1016/j.ecl.2021.05.012>.

Diabetes Symptoms | CDC (2023). Available at: <https://www.cdc.gov/diabetes/basics/symptoms.html> (Accessed 7 Aug 2024).

Foretz M, Guigas B, Viollet B. ‘Metformin: update on mechanisms of action and repurposing potential’. *Nat Rev Endocrinol*. 2023 Aug;19(8):460-476. doi: 10.1038/s41574-023-00833-4. Epub 2023 May 2. PMID: 37130947; PMCID: PMC10153049.

Goyal R, Singhal M, Jialal I. ‘Type 2 Diabetes’. [Updated 2023 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK513253/>

Gomes, M.B. et al. (2019) ‘Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global discover study’, *Diabetes Research and Clinical Practice*, 151, pp. 20–32. doi:10.1016/j.diabres.2019.03.024.

Haymana, C. *et al.* (2021) ‘Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes – a nationwide cross-sectional study (TEMED treatment study)’, *Diabetes Research and Clinical Practice*, 171, p. 108556. doi:10.1016/j.diabres.2020.108556.

Hurren, Kathryn M., and Marissa Waldman Dunham. “Are Thiazolidinediones a Preferred Drug Treatment for Type 2 Diabetes?” *Expert Opinion on Pharmacotherapy*, vol. 22, no. 2, 7 Dec. 2020, pp. 131–133, <https://doi.org/10.1080/14656566.2020.1853100>. Accessed 1 Aug. 2021.

International Diabetes Federation. (2021) *IDF Diabetes Atlas*. 10th edn. Available at: <https://diabetesatlas.org/> (Accessed: 7 August 2024).

Jack, Gwendolyne Anyanate, and Sangeeta R Kashyap. “Insulin Independence with SGLT2 Inhibitor Use in Type 2 Diabetes.” *The Journal of Clinical Endocrinology & Metabolism*, vol. 108, no. 10, 22 Mar. 2023, pp. e1153–e1154, doi.org/10.1210/clinem/dgad143, <https://doi.org/10.1210/clinem/dgad143>. Accessed 26 Dec. 2024.

Keating GM. ‘Vildagliptin: a review of its use in type 2 diabetes mellitus’. *Drugs*. 2014 Apr;74(5):587-610. doi: 10.1007/s40265-014-0199-3. PMID: 24638989.

Kementerian Kesehatan RI (2018) *Hasil Utama Riset Kesehatan Dasar (Riskesdas) 2018*. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian RI.

Kramer, Caroline K., et al. “Insulin and Insulin Analogs as Antidiabetic Therapy: A Perspective from Clinical Trials.” *Cell Metabolism*, vol. 33, no. 4, 6 Apr. 2021, pp. 740–747, www.sciencedirect.com/science/article/pii/S1550413121001212, <https://doi.org/10.1016/j.cmet.2021.03.014>.

Kyrou, I. et al. (2020) ‘Sociodemographic and lifestyle-related risk factors for identifying vulnerable groups for type 2 diabetes: A narrative review with emphasis on data from Europe’, *BMC Endocrine Disorders*, 20(S1). doi:10.1186/s12902-019-0463-3.

LaMoia TE, Shulman GI. ‘Cellular and Molecular Mechanisms of Metformin Action’. *Endocr Rev*. 2021 Jan 28;42(1):77-96. doi: 10.1210/endrev/bnaa023. PMID: 32897388; PMCID: PMC7846086.

Mandal, Sekhar *et al.* (2016) ‘Drug utilization study in patients with type 2 diabetes mellitus attending diabetes clinic of a tertiary care hospital in rural Bengal’, *International Journal of Basic and Clinical Pharmacology*, pp. 1647–1654. doi:10.18203/2319-2003.ijbcp20162487.

Maruthur, N.M., Tseng, E., Hutfless, S., Wilson, L.M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J.B., Bolen, S., 2016b. Diabetes medications as monotherapy or metformin- based combination therapy for type 2 diabetes: A systematic review and meta-analysis. *Ann. Intern. Med.* <https://doi.org/10.7326/M15-2650>

Meena, Dinesh & Jayanthi, M. (2019). Drug utilization research: a review. *International Journal of Basic & Clinical Pharmacology*, 8(2), p.354.

Menteri Kesehatan Republik Indonesia. (2020) *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/603/2020 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Diabetes Melitus Tipe 2 Dewasa*.

Nauck, Michael A., et al. "GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes – State-of-The-Art." *Molecular Metabolism*, vol. 46, no. 46, Apr. 2021, p. 101102, www.ncbi.nlm.nih.gov/pmc/articles/PMC8085572/, <https://doi.org/10.1016/j.molmet.2020.101102>.

Overbeek, J.A. *et al.* (2017) 'Type 2 diabetes mellitus treatment patterns across Europe: A population-based multi-database study', *Clinical Therapeutics*, 39(4), pp. 759–770. doi:10.1016/j.clinthera.2017.02.008.

PERKENI (2021). 'Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia'. PB PERKENI, Jakarta.

Quintanilla Rodriguez BS, Mahdy H. Gestational Diabetes. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK545196/>

Sanabria-de la Torre, R., García-Fontana, C., González-Salvatierra, S., Andújar-Vera, F., Martínez-Heredia, L., García-Fontana, B., & Muñoz-Torres, M. (2022). 'The Contribution of Wnt Signaling to Vascular Complications in Type 2 Diabetes Mellitus', *International Journal of Molecular Sciences*, 23(13), 6995. <https://doi.org/10.3390/ijms23136995>

Tomlinson B, Patil NG, Fok M, Chan P, Lam CWK. 'The role of sulfonylureas in the treatment of type 2 diabetes'. *Expert Opin Pharmacother*. 2022 Feb;23(3):387-403. doi: 10.1080/14656566.2021.1999413. Epub 2021 Nov 10. PMID: 34758676.

World Health Organization, 2003. Introduction to Drug Utilization Research.

Wu, Y., Ding, Y., Tanaka, Y., & Zhang, W. (2014). 'Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention', *International Journal of Medical Sciences*, 11(11), 1185–1200. <https://doi.org/10.7150/ijms.10001>

Yan, Zihui, et al. "The Interaction between Age and Risk Factors for Diabetes and Prediabetes: A Community-Based Cross-Sectional Study." *Diabetes, Metabolic Syndrome and Obesity*, vol. Volume 16, no. 16, Jan. 2023, pp. 85–93, www.ncbi.nlm.nih.gov/pmc/articles/PMC9843502/, <https://doi.org/10.2147/dms.o.s390857>.